This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who
underwent radical resection will be included. The patients will be randomized to group A
(receive CIK treatment) or group B (just regularly follow up) without any anti-cancer
treatment after resection of HCC, and the randomize ratio will be 1:1.